Get the Stockscreener App
1.96
2.00%
-0.04
After Hours:
1.99
0.03
+1.53%
Inovio Pharmaceuticals Inc stock is traded at $1.96, with a volume of 500.39K.
It is down -2.00% in the last 24 hours and down -14.04% over the past month.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
See More
Previous Close:
$2.00
Open:
$2
24h Volume:
500.39K
Relative Volume:
0.53
Market Cap:
$70.39M
Revenue:
$832.00K
Net Income/Loss:
$-135.12M
P/E Ratio:
-0.3218
EPS:
-6.09
Net Cash Flow:
$-124.69M
1W Performance:
-6.22%
1M Performance:
-14.04%
6M Performance:
-77.18%
1Y Performance:
-62.95%
1-Day Range:
$1.905
$2.04
1-Week Range:
$1.90
$2.06
52-Week Range:
$1.74
$14.75
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
6769 MESA RIDGE RD., SAN DIEGO, PA
Compare INO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.96 | 70.39M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $12.40 Average Price Target from Brokerages - MarketBeat
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $12.40 - Defense World
DNA Nanotechnology Market Overall Study Report 2025-2032 | - openPR
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
BlackRock, Inc. Expands Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Anal Cancer Market Forecast 2034: Clinical Trials, Medication, - openPR
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
INOVIO Reports Inducement Grant Under Inducement Plan - GuruFocus.com
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
INOVIO to Present at Oppenheimer Healthcare Life Sciences Conference - MyChesCo
Vanguard Group Inc. Reduces Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - StreetInsider.com
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
INOVIO's Next Big Move: CEO Reveals Future of DNA Medicine at Major Healthcare Conference - StockTitan
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Head to Head Review: Inovio Pharmaceuticals (NASDAQ:INO) and Hypertension Diagnostics (OTCMKTS:HDII) - Defense World
INOVIO Reports Promising Long-Term Data for INO-3107 in Treating RRP - MSN
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharma Stock Slips Ahead of Q3 Earnings: Retail’s Bullish - MSN
Barclays PLC Buys 25,116 Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
INOVIO Targets 2025 as Transformational Year with Major Progress on INO-3107 - MSN
What is HC Wainwright’s Estimate for INO FY2024 Earnings? - Defense World
Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock? - MSN
Inovio Pharmaceuticals (NASDAQ:INO) Given New $3.00 Price Target at HC Wainwright - Defense World
Anal Cancer Market on Track for Major Expansion by 2034, - openPR
Inovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $3.00 by Analysts at HC Wainwright - MarketBeat
JMP Securities Reaffirms “Market Outperform” Rating for Inovio Pharmaceuticals (NASDAQ:INO) - Defense World
Inovio Pharmaceuticals' SWOT analysis: dna-based immunotherapy firm faces hurdles - Investing.com Australia
Inovio Pharmaceuticals' SWOT analysis: dna-based immunotherapy firm faces hurdles By Investing.com - Investing.com South Africa
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $11.50 - MarketBeat
Inovio Pharmaceuticals' (INO) "Market Outperform" Rating Reiterated at JMP Securities - MarketBeat
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accom - GuruFocus.com
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments - Longview News-Journal
What's Going On With Inovio Pharmaceuticals (INO) Stock? - Benzinga
Why Inovio Pharmaceuticals (INO) Stock Is Skyrocketing - Benzinga
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares Purchased by Geode Capital Management LLC - Defense World
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares Purchased by State Street Corp - Defense World
Inovio Pharmaceuticals Q3 Earnings Tops Estimates, Lifts Retail Sentiment - MSN
Inovio Completes Enrollment In The Phase 1 U.S. Trial Of Ino-4800 For Covid-19 Dna Vaccine Interim Results Expected In June - Reuters
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):